gas exchange in the artificial lung

iLA Membrane Ventilator

A special hollow-fiber membrane assumes the function of pulmonary alveoli.

Effective and reliable: the iLA Membrane Ventilator® (Source: Novalung Support Registry 2008)

The iLA Membrane Ventilator® is the first artificial lung that breathes for the patient outside the body. It removes carbon dioxide outside of the lung, and is perfused by the heart like a natural organ. This relieves the patient’s lung by providing gas exchange support and reducing the workload for the breathing pump. The lung is given “Time to Heal“®.
The iLA Membrane Ventilator® is sometimes referred to in scientific articles as “pecla“ (pumpless extracorporeal lung assist) or ”AVCO2R“ (arterio-venous CO2 removal).

Gas exchange via artificial alveoles

A hollow-fiber membrane is responsible for gas exchange in the artificial lung, which measures only 14 by 14 cm, supporting or even replacing mechanical ventilation. The iLA Membrane Ventilator® is connected to the patient via two NovaPort® femoral cannulas in an arterio-venous circuit. The absence of a mechanical blood pump reduces the risk of inflammatory reactions.

How it works: effective and reliable

The iLA Membrane Ventilator® incorporates a heparin-coated hollow-fiber diffusion membrane and removes carbon dioxide effectively and reliably in a very short period of time to achieve the desired target, using low blood flows of approx. 1 L/min. This extrapulmonary ventilation can be controlled via the sweep gas flow. In cases of respiratory acidosis the pH is generally returned to normal physiological levels within a few hours. This can help protect the kidney and other organs and prevent multi-organ failure.

Easy to use and easy to care for

Positioning therapy and initial mobilization are possible with the iLA Membrane Ventilator thanks to the 360° rotating curve connectors. It is also been used for both inter-hospital and intra-hospital transport. The iLA Membrane Ventilator® was developed for temporary use in intensive-care patients and is approved in Europe for up to 29 days.

click to see the NovaLung official site

gas exchange in the artificial lung by NovaLung /Ila

Gas exchange via artificial alveoles

A hollow-fiber membrane is responsible for gas exchange in the artificial lung, which measures only 14 by 14 cm, supporting or even replacing mechanical ventilation. The iLA Membrane Ventilator® is connected to the patient via two NovaPort® femoral cannulas in an arterio-venous circuit. The absence of a mechanical blood pump reduces the risk of inflammatory reactions.

see moe on this new lung Ila product

Novalung receives CE mark

Novalung receives CE mark for iLA activve With the new all-rounder for extrapulmonary lung support Novalung GmbH is the only company worldwide offering the complete portfolio for both pumpless and pump-driven lung support.

Novalung announces receiving CE mark approval for their new pump-driven iLA activve® lung support system. It will be launched in Europe with immediate effect.

Respiratory support with iLA activve® enables a treatment environment with awake, mobile patients instead of sedated patients on invasive mechanical ventilation that causes further damage to the lung and other organs. The iLA activve® is thus a major step towards replacing invasive mechanical ventilation.

Different patient populations and types of lung failure place varying demands on optimal respiratory support. To cover all extrapulmonary support needs with one system platform, the iLA activve® has been developed as a flexible all-rounder. The iLA activve® with veno-venous cannulation covers the full range of respiratory support, from highly effective carbon dioxide elimination to complete oxygenation. Core elements are the iLA Membrane Ventilator®, the only gas exchanger specifically designed for long-term respiratory support, and the iLA activve® pump which surpasses all previously available blood pumps in its performance, broad range of blood flow, and blood protection characteristics.

The iLA activve® system has been specifically configured to allow patients to move about during respiratory support. Therefore all necessary components are mounted on an easily movable trolley. Furthermore the iLA Membrane Ventilator® and the iLA activve® pump are height-adjustable via a quick-release handle. “This allows physicians, respiratory therapists and nurses to adjust the system to the patient’s individual needs, whether the patient is in bed, sits up or even walks”, explains Dr. Georg Matheis, Managing Director of Novalung.

The range of applications of the iLA Membrane Ventilator® technology has broadened substantially. While severe acute lunge failure (ARDS) was the typical indication in the early days, today exacerbations of chronic lung disease (COPD) comprise a growing application of the iLA Membrane Ventilator®. Novalung will launch several additional products for the iLA activve® platform throughout this year.

click for official Novalung

World Lung Foundation

Our Mission at the World Lung Foundation

To improve the lives of individuals across the world by strengthening community capacity to prevent and manage lung disease.

Since 2004, WLF has emerged as a dynamic public health organization with expertise in project management, capacity building, health communications and information, and operational research.





click to the offical World Lung Foundation website

100 year life span: coming soon ???

100-yr life span to be common soon Deccan Chronicle 2011-01-27


Hyderabad, Jan. 26: Satapoorti, or celebration of a person’s 100th birthday will become common in the next three decades as the average life span of people increases by 20 years, says eminent geneticist and biotechnologist Dr Krishna Dronamraju.
“It is only a matter of time. In the next 30 years, the average life span will increase by at least 15 years, if not 20 years. Once this happens, Sashtipoorti (celebration of 60th birthday) will be passé. Satapoorti will be the in-thing, as many people will live beyond 100,” Dr Dronamraju said.

Sashtipoorti was celebrated because any one living beyond 50 years was considered a miracle and thus warranted a celebration. Now that most people live beyond the age of 70, Sashtipoorti has lost its flavour.
“We should now look forward to Satapoorti,” said the India-born scientist who now lives in the United States.
Dr Dronamraju, who is also an adviser to the US government on health and agriculture, says the average life span has increased by 20 years in the last 50 years, and with pioneering research in genetics, stem cells and nanotechnology, people may live beyond 100 years.
Advanced gene therapy will help in strengthening the heart muscles so that it can work longer.
Strengthening heart, lungs, blood vessels and kidneys through gene therapy will improve not only the quality of life, but also the overall life span.

At best, a human being can live up to 150 years. “There’s a lot of wear and tear in the body, but we can postpone death. An artificial heart is almost a reality. Considerable research has been done in lung transplant. Once artificial heart and lung transfer become practical, we can prolong human life.”

Many people living in the Caucasus Mountains are known to live beyond 100 years, Dr Dronamraju said. Research studies show that these people avoid fatty substances in their diet. “The body needs a lot of dietary fibre and the best source is through vegetables and fruits,” he said, providing the recipe for a long and healthy life

Wearable Kidney will a Wearable lung be next ?

Wearable Kidney will a Wearable lung be next ?

 

Wearable Kidney

For people with failing kidneys, basic necessities of life like removing toxins from the blood and keeping fluid levels balanced requires hours hooked up to a dialysis machine the size of a clothes dryer. But a new, portable artificial kidney, small and light enough to fit on a belt system, could change that. Despite its small size, the automated, wearable artificial kidney (AWAK), designed by Martin Roberts and David B.N. Lee of UCLA, actually works better than traditional dialysis because it can be used 24 hours a day, seven days a week, just like a real kidney.

 

 

 

see the top 10 Bionic tech devices

Novalung and Medos start cooperation

Due to the acquisition of Medos Medizintechnik AG by the private equity fund Zukunftsfonds Heilbronn (“Future Fund of Heilbronn”) the company will cooperate closely in the future with Novalung GmbH, which is expected to strengthen both medical device companies.

The Zukunftsfonds Heilbronn (zfhn) announced that it has acquired Medos Medizintechnik AG from Ventizz Capital Partners Advisory AG. The purchase agreement was signed on January 7, 2011. With this acquisition medical device technology has become the most important sector for the private equity fund. Thomas Villinger, Managing Director of the zfhn, explained the decision behind this acquisition: ”The medical device sector is characterized by solid growth and is independent of economic cycles.“ He noted further that “Medos and Novalung are technological leaders is different markets, namely cardiac support and lung support. Their innovative technologies complement one another extremely well, and a close cooperation will enable even better utilization and speed up further developments.“

Dr. Volker Hamm, who has been named to join the Medos Management Board, noted with pleasure: “We are very happy about this development. Novalungs excellent market know-how in the field of lung support will provide a much broader customer base for our high-tech products.“ Hamm also noted that Christian Palme will join Thomas Villinger on the Supervisory Board of Medos. The Medos facilities in Stolberg und Radeberg will continue their operations after the acquisition.

Dr. Georg Matheis, Managing Director of Novalung GmbH since its founding eight years ago, emphasized that Novalung, after thousands of treatments using the company’s artificial lung, the iLA Membrane Ventilator®, has firmly established itself. “The innovative therapy for the treatment of lung failure without invasive mechanical ventilation is now well accepted” the former cardiothoracic surgeon noted. ”In order to further expand our market leadership as the pioneering company in this field, we will develop a full product portfolio in 2011. With the cooperation with Medos this can be accomplished more quickly than we originally expected.“ Matheis also pointed to the newest member of Novalung’s executive management team, Josef Bogenschütz, who left medical device company Maquet and join Novalung just a few weeks earlier. “In addition to strong leadership, Josef Bogenschütz brings with him great expertise in the development and manufacturing of artificial lungs. With him on board we are ideally positioned to aggressively develop additional innovative solutions for the replacement of invasive mechanical ventilation. Together, and with the support of our clinical partners, we will realize the vision of increasingly avoiding the damage of invasive mechanical ventilation.“

Bogenschütz, who most recently drove the successful growth of Maquet Cardiopulmonary AG as President and CEO, is equally optimistic concerning the expansion of the zfhn portfolio. ”I am pleased that this new cooperation provides so many areas of synergy for both companies. We will jointly leverage our know-how in the high-end cleanroom manufacturing of artificial lungs to further optimize our manufacturing efficiencies.“ He also presented Novalungs core strategy to intensify the company’s research and development activities and to further expand sales in the core markets in Europe and the USA.

see more info on this external lung device
http://www.openpr.com/news/159889/Novalung-and-Medos-start-cooperation.html